G1 Therapeutics Inc (NASDAQ:GTHX) insider Rajesh Malik sold 3,776 shares of the firm’s stock in a transaction dated Thursday, November 15th. The stock was sold at an average price of $39.75, for a total value of $150,096.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Rajesh Malik also recently made the following trade(s):
- On Monday, September 17th, Rajesh Malik sold 3,776 shares of G1 Therapeutics stock. The stock was sold at an average price of $66.08, for a total value of $249,518.08.
Shares of NASDAQ GTHX traded down $0.46 during midday trading on Friday, hitting $41.35. The stock had a trading volume of 255,449 shares, compared to its average volume of 318,762. The firm has a market capitalization of $1.50 billion, a P/E ratio of -11.58 and a beta of 1.16. G1 Therapeutics Inc has a 1-year low of $18.03 and a 1-year high of $69.57.
A number of analysts have issued reports on the company. JPMorgan Chase & Co. raised their price target on G1 Therapeutics from $58.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, August 10th. Needham & Company LLC decreased their price target on G1 Therapeutics from $76.00 to $74.00 and set a “buy” rating on the stock in a research note on Thursday, November 8th. BTIG Research assumed coverage on G1 Therapeutics in a research note on Monday, September 10th. They issued a “buy” rating and a $80.00 price target on the stock. BidaskClub lowered G1 Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 25th. Finally, HC Wainwright reissued a “buy” rating and issued a $79.00 price target on shares of G1 Therapeutics in a research note on Monday, September 17th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $74.00.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Teachers Advisors LLC lifted its stake in shares of G1 Therapeutics by 4.8% in the 3rd quarter. Teachers Advisors LLC now owns 42,587 shares of the company’s stock valued at $2,227,000 after purchasing an additional 1,944 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of G1 Therapeutics by 78.5% in the 3rd quarter. AQR Capital Management LLC now owns 19,051 shares of the company’s stock valued at $996,000 after purchasing an additional 8,381 shares in the last quarter. MetLife Investment Advisors LLC lifted its stake in shares of G1 Therapeutics by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 14,980 shares of the company’s stock valued at $783,000 after purchasing an additional 5,325 shares in the last quarter. Signaturefd LLC lifted its stake in shares of G1 Therapeutics by 38.1% in the 3rd quarter. Signaturefd LLC now owns 20,942 shares of the company’s stock valued at $1,095,000 after purchasing an additional 5,780 shares in the last quarter. Finally, Pacer Advisors Inc. acquired a new position in shares of G1 Therapeutics in the 3rd quarter valued at about $111,000. 69.37% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “G1 Therapeutics Inc (GTHX) Insider Rajesh Malik Sells 3,776 Shares of Stock” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://sportsperspectives.com/2018/11/17/g1-therapeutics-inc-gthx-insider-rajesh-malik-sells-3776-shares-of-stock.html.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Featured Story: Understanding Market Liquidity
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.